STOCK TITAN

Simulations Plus to Present at 23rd Annual Needham Virtual Growth Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 23rd Annual Needham Virtual Growth Conference on Thursday, January 14, 2021, at 2:00 p.m. ET. In addition to his presentation, Mr. O’Connor will host one-on-one meetings throughout the day.

This year’s conference will provide shareholders and investors the opportunity to see presentations from nearly 500 leading public and private companies in several structured and user-friendly virtual settings. For more information about the conference or to schedule a one-on-one meeting with Mr. O’Connor, please contact Hayden IR at slp@haydenir.com.

About Simulations Plus, Inc.

Simulations Plus, Inc. is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com.

Follow us on Twitter | LinkedIn | YouTube

Simulations Plus, Inc.

NASDAQ:SLP

SLP Rankings

SLP Latest News

SLP Stock Data

963.47M
16.19M
18.89%
78.83%
6.01%
Computer Systems Design Services
Professional, Scientific, and Technical Services
Link
United States of America
LANCASTER

About SLP

simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res